

August 9, 2018

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip code: 512529

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051
Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Outcome of Board Meeting: Unaudited financial results for the quarter ended June 30, 2018

Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its meeting held today i.e. August 9, 2018 have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2018. In this regard, kindly find attached the following:

1. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2018.
2. Press Release on Financial Results alongwith with investors presentation
3. Limited Review Report issued by the Statutory Auditors of the Company

The Board Meeting commenced on 11:15 A.M. and concluded at 01:44 P.M.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited


Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22, Wagle Industrial Area, Thane (W), Mumbai – 400604, India

Tel: +91 22 41114777 | FAX: +91-22-41114754 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

3. The Statement includes the results of the following entities:

- i) Alivira Animal Health Australia Pty Ltd;
- ii) Alivira Animal Health Limited, Ireland;
- iii) Alivira Animal Health Limited, India;
- iv) Alivira Saude Animal Brasil Participacoes Ltda;
- v) Alivira UA Limited;
- vi) Alivira France
- vii) Bremer Pharma GMBH;
- viii) Comercial Vila Veterinaria de Lleida S.L;
- ix) Elysian Life Sciences Private Limited;
- x) Fendigo BV;
- xi) Fendigo SA;
- xii) Interchange Veterinária Indústria E Comércio Ltda;
- xiii) Laboratorios Karizoo, S.A;
- xiv) Laboratorios Karizoo, S.A. De C.V. (Mexico);
- xv) N-Vet AB;
- xvi) Phytotherapic Solutions S.L;
- xvii) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
- xviii) SeQuent Antibiotics Private Limited;

WJ

Deloitte Haskins & Sells

- xix) SeQuent Pharmaceuticals Private Limited;
- xx) SeQuent Research Limited;
- xxi) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
- xxii) Vila Viña Participacions S.L ;

4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of twelve subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.16,443.46 lakhs for the quarter ended June 30, 2018, and total profit after tax of Rs.534.79 lakhs and total comprehensive income of Rs.534.79 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. The consolidated unaudited financial results includes the interim financial results of nine subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue Rs.434.72 lakhs for the quarter ended June 30, 2018, and total loss after tax of Rs.806.15 lakhs and total comprehensive loss of Rs.802.15 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner
(Membership No. 206920)


Mumbai, August 9, 2018
SPK/JKS/2018

SEQUENT SCIENTIFIC LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(Rs. in Lakhs)

	Particulars	3 months ended 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
		UNAUDITED	AUDITED (Refer note 11)	UNAUDITED	AUDITED
I	Revenue from operations (Refer note 5)	23,515.20	23,275.86	19,423.20	84,944.80
II	Other income	181.40	291.86	362.30	1,658.10
III	Total Income (I+II)	23,696.60	23,567.72	19,785.50	86,602.90
IV	Expenses				
	(a).Cost of materials consumed	10,507.60	10,706.92	7,948.12	34,459.40
	(b).Purchase of stock-in-trade	3,354.70	3,231.42	3,485.56	14,184.10
	(c).Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,211.20)	(1,590.06)	(825.00)	(2,394.30)
	(d).Excise duty on sale of goods	-	-	161.02	161.02
	(e).Employee benefits expense	3,513.60	2,893.77	2,681.59	11,382.80
	(f). Finance costs	778.30	967.56	610.37	3,306.90
	(g).Depreciation and amortisation expense	953.80	948.07	1,008.31	4,134.30
	(h).Other expense	5,098.90	5,008.87	4,464.46	18,853.80
	Total expenses	23,005.70	22,166.55	19,534.43	84,088.02
V	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	690.90	1,401.17	251.07	2,514.88
VI	Exceptional items loss/ (gain) (net) (Refer note 6)	-	150.40	-	150.40
VII	Profit/(loss) from continuing operations before tax (V-VI)	690.90	1,250.77	251.07	2,364.48
VIII	Tax expense				
	(a).Current tax	340.70	52.93	223.30	1,196.80
	(b). MAT credit entitlement	(84.80)	(3.90)	-	(3.90)
	(c). MAT credit entitlement written off	-	286.70	-	286.70
	(d).Deferred tax	(13.00)	71.80	(30.70)	(133.90)
	Total tax expenses (VIII)	242.90	407.53	192.60	1,345.70
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	448.00	843.24	58.47	1,018.78
X	Profit/(loss) from discontinued operations	-	-	166.23	1,054.70
	Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations	-	39,264.00	-	41,009.50
	Tax expense of discontinued operation				
	(a).Current tax	-	-	-	362.73
	(b). MAT credit entitlement	-	(362.73)	-	(362.73)
	Profit/(loss) from discontinued operations after tax (Refer note 4)	-	39,626.73	166.23	42,064.20
XI	Profit/(loss) for the period (IX+X)	448.00	40,469.97	224.70	43,082.98
XII	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a).Re-measurement gain/(loss) on defined benefits plans	(5.00)	92.41	(3.60)	82.50
	(b).Fair value gain / (loss) from investment in equity instruments	(7,711.90)	(5,099.01)	(3,230.80)	(14,195.41)
	Items that may be reclassified to profit or loss				
	(a).Exchange differences on translation of foreign operations	(136.56)	162.16	(66.10)	244.66
	(b).Exchange differences on net investment in foreign operations	355.51	288.54	98.80	(3.61)
	Total other comprehensive income	(7,497.95)	(4,555.90)	(3,201.70)	(13,871.86)
XIII	Total comprehensive income for the period (XI+XII)	(7,049.95)	35,914.07	(2,977.00)	29,211.12
	Profit for the period attributable to:				
	- Owners of the Company	328.00	39,954.87	223.70	42,156.58
	- Non-controlling interests	120.00	515.10	1.00	926.40
	Other comprehensive income for the period attributable to:				
	- Owners of the Company	(7,433.45)	(4,588.50)	(3,269.00)	(13,954.86)
	- Non-controlling interests	(64.50)	32.60	67.30	83.00
	Total comprehensive income for the period attributable to:				
	- Owners of the Company	(7,105.45)	35,366.37	(3,045.30)	28,201.72
	- Non-controlling interests	55.50	547.70	68.30	1,009.40
	Earnings per equity share: (face value of Rs. 2 each) (not annualised)				
	- for continuing operations				
	(1) Basic (in Rs.)	0.14	0.14	(0.13)	(0.11)
	(2) Diluted (in Rs.)	0.13	0.13	(0.13)	(0.11)
	- for discontinued operations				
	(1) Basic (in Rs.)	-	16.36	0.22	17.51
	(2) Diluted (in Rs.)	-	16.25	0.22	17.40
	- for continuing and discontinued operations				
	(1) Basic (in Rs.)	0.14	16.50	0.09	17.40
	(2) Diluted (in Rs.)	0.13	16.38	0.09	17.29
	See accompanying notes to the financial results				



SEQUENT SCIENTIFIC LIMITED

Notes:

1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 9 August 2018.
2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

(Rs in Lakhs)

Particulars	3 months ended 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	UNAUDITED	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Revenue from continuing operations	2,628.50	2,679.50	2,728.20	10,723.60
Profit/ (Loss) before tax from continuing operations	261.90	(170.40)	(273.50)	66.30
Profit/ (Loss) after tax from continuing operations	261.90	(404.92)	(273.50)	(220.37)
Profit/ (Loss) after tax from discontinued operations	-	39,516.43	826.70	40,861.10
Total comprehensive income	(7,459.00)	33,978.45	(2,675.70)	26,408.03

4a. Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018 ('Order'), with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited ('Solara').

Pursuant to the above, Sequent Penems Private Limited has ceased to be the subsidiary of the Company.

In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the results of Human API business and Sequent Penems Private Limited which had revenue of Rs. 8,470.00 lakhs and expenses of Rs. 7,650.51 lakhs.

4b. During the previous year ended 31 March 2018, the Company completed the divestment of woman healthcare business (discontinued operations).

The results relating to discontinued business are as follows:

(Rs in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Total income	-	10,225.92	18,575.74
Total expenses	-	10,059.69	17,521.04
Profit/ (Loss) before exceptional items and tax	-	166.23	1,054.70
Exceptional items	-	-	-
Profit/ (Loss) before tax	-	166.23	1,054.70
Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations	39,264.00	-	41,009.50
Tax Expense of discontinued operations	(362.73)	-	-
Profit/ (Loss) for the period	39,626.73	166.23	42,064.20

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty up to 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.

6. Exceptional Items:

(Rs in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Previous year ended 31-Mar-2018
	AUDITED (Refer note 11)	AUDITED
- Write off of ineligible GST credits	116.10	116.10
- Goodwill impairment	790.00	790.00
- Contingent consideration reversal	(931.26)	(931.26)
- liability towards pre-acquisition employee claims	175.56	175.56
Total	150.40	150.40

7. With effect from 01 April 2018, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GmbH (Bremer). The Company is in process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted for based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations". The results for the quarter ended 30 June 2018 includes Revenue from operations Rs. 128.30 lakhs and Loss after tax Rs. 4.53 lakhs relating to Bremer.

8. During the quarter, the Company has revised the useful life of certain acquired intangibles from 5 years to 20 years. Had the useful life been 5 years, the profit for the quarter ended 30 June 2018 would have reduced by Rs. 167.55 lakhs (net of deferred tax Rs. 54.09 lakhs).

9. 'Ind AS 115 - Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.

10. The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.


11. The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

12. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish Gupta

Manish Gupta
Managing Director



Place : Mumbai
Date : 9 August 2018

W

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner

Membership No. 206920)

Mumbai, August 09, 2018
SPK/JKS/2018

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in previous year	Previous year ended
		30-Jun-2018	31-Mar-2018	30-Jun-2017	31-Mar-2018
		Unaudited	Audited (Refer note 10)	Unaudited	Audited
I	Revenue from operations (Refer note 3)	2,628.50	2,679.50	2,728.20	10,723.60
II	Other income	435.60	509.40	443.90	2,426.90
III	Total income (I+II)	3,064.10	3,188.90	3,172.10	13,150.50
IV	Expenses				
	(a) Cost of materials consumed	916.10	1,102.20	581.00	3,065.70
	(b) Purchases of stock-in-trade	1,026.60	948.10	1,262.00	4,914.30
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(160.80)	(35.10)	0.30	(42.20)
	(d) Excise duty on sale of goods	-	-	122.90	122.90
	(e) Conversion and processing charges	398.00	417.88	238.20	1,175.60
	(f) Employee benefits expense	157.50	182.50	363.60	1,185.00
	(g) Finance costs	1.30	8.10	17.50	39.20
	(h) Depreciation and amortisation expense	87.70	114.40	75.50	366.70
	(i) Other expenses	375.80	505.12	784.60	2,140.90
	Total expenses (IV)	2,802.20	3,243.20	3,445.60	12,968.10
V	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	261.90	(54.30)	(273.50)	182.40
VI	Exceptional items (gain) / loss (Refer note 7)	-	116.10	-	116.10
VII	Profit/(loss) from continuing operations before tax (V-VI)	261.90	(170.40)	(273.50)	66.30
VIII	Tax expense				
	(a) Current tax	55.60	(48.28)	-	3.87
	(b) MAT credit entitlement	(55.60)	(3.87)	-	(3.87)
	(c) MAT credit entitlement written off	-	286.67	-	286.67
	Total tax expenses (VIII)	-	234.52	-	286.67
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	261.90	(404.92)	(273.50)	(220.37)
X	Profit/(loss) from discontinued operations	-	-	826.70	1,707.40
	Gain on demerger of Human API business	-	39,153.70	-	39,153.70
	Tax expense of discontinued operations				
	(a) Current tax	-	-	-	362.73
	(b) MAT credit entitlement	-	(362.73)	-	(362.73)
	Profit/(loss) from discontinued operations after tax (X) (Refer note 9)	-	39,516.43	826.70	40,861.10
XI	Profit/(loss) for the period (IX+X)	261.90	39,111.51	553.20	40,640.73
XII	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurements of defined benefits plans	(9.00)	(34.06)	1.90	(37.30)
	(b) Fair value gain / (loss) from investment in equity instruments (net)	(7,711.90)	(5,099.00)	(3,230.80)	(14,195.40)
	Total other comprehensive income for the period (XII)	(7,720.90)	(5,133.06)	(3,228.90)	(14,232.70)
XIII	Total comprehensive income for the period (XI+XII)	(7,459.00)	33,978.45	(2,675.70)	26,408.03
XIV	Earnings per equity share: (Face value of Rs. 2 each) (not-annualised)				
	- for continuing operations				
	(1) Basic (in Rs.)	0.11	(0.17)	(0.11)	(0.09)
	(2) Diluted (in Rs.)	0.11	(0.17)	(0.11)	(0.09)
	- for discontinued operations				
	(1) Basic (in Rs.)	-	16.31	0.34	16.86
	(2) Diluted (in Rs.)	-	16.20	0.34	16.75
	- for continuing and discontinued operations				
	(1) Basic (in Rs.)	0.11	16.14	0.23	16.77
	(2) Diluted (in Rs.)	0.11	16.03	0.23	16.66
	See accompanying notes to financial results				



Notes:

- 1 The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 August 2018.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty upto 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.
- 4 During the quarter, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GMBH.
- 5 'Ind AS 115- Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 6 The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.
- 7 Exceptional items for the quarter and year ended 31 March 2018 comprises write-off of ineligible GST credits.
- 8 Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entity and for previous periods, tax expenses are split between continuing and discontinued operations based on book profits from the respective operations.
- 9 Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018, with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited. In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the result of the Human API business which had a revenue of Rs. 8,461.60 lakhs and expenses of Rs. 7,634.90 lakhs.

(Rs. in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	Audited (Refer note 10)	Unaudited	Audited
Total income	-	8,461.60	16,795.60
Total expenses	-	7,634.90	15,088.20
Profit/(loss) before exceptional items and tax	-	826.70	1,707.40
Exceptional items	-	-	-
Profit/(loss) before tax	-	826.70	1,707.40
Gain on demerger of Human API business	39,153.70	-	39,153.70
Tax expense	(362.73)	-	-
Profit/(loss) for the period	39,516.43	826.70	40,861.10

- 10 The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.
- 11 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited



Manish Gupta
Manish Gupta
Managing Director

Place : Mumbai
Date : 09 August 2018

W

Leading with Vision.
Building with Passion.
India's No. 1 animal health company



Q1'19 Presentation for the Investors | August 9, 2018

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.



Q1'19 Performance Review



A robust beginning of the financial year



Manish Gupta
MD, Sequent



We delivered robust growth in revenue with our improved operating leverage leading to a 300 basis point improvement in the margins. The performance would have been even better had we not witnessed the currency headwinds in Turkey (-17%) and Brazil (-10%) coupled with regulatory changes in Turkey which impacted our primary sales.

Our recent Bremer acquisition in Germany has helped us shape a valuable injectables strategy for regulated markets. With 12 API filings in US, we have the largest filings for any generic companies in US. We stay confident of delivering the strategic and financial outcomes for FY19 as our API business gains momentum and Europe gains further traction driven by ~25 new launches planned across geographies.

Revenues (₹ mn)



QoQ


21.1%

EBITDA (₹ mn)



300_{bps}

Profit After Tax (₹ mn)




7.5x




1.7x EBITDA growth despite currency headwinds

All values in ₹ mn

EBITDA bridge (Q1'19 vs Q1'18)



EBITDA bridge (Q1'19 vs Q4'18)



Key Highlights

- Improved performance across all businesses resulting in an expansion of ~700bps in operating margins over Q1'18
 - Sustainable EBITDA now ~₹345 mn
 - Sustainable operating margins now at 14.7%
- Sustainable operating margins expand ~150bps over Q4'18



Significant ramp up in Europe and key EMs

All values in ₹ mn

Geography-wise Sales	Q1'19	Q1'18	YoY%	YoY% (Constant currency)
APIs	602	521	15.5%	12.3%
Formulations	1,750	1,422	23.1%	18.2%
Europe	927	720	28.7%	14.2%
Turkey	243	245	-0.9%	16.2%
Emerging Markets	374	265	40.6%	37.6%
LATAM	206	190	8.3%	17.1%
Global Sales	2,352	1,942	21.1%	17.1%

Key Highlights

- Overall business has grown by 14.5% over Q1 FY18, without considering Bremer
 - API Business grew by 15.5%
 - Formulations business grew by 12.9% (without Bremer), significantly ahead of 6% industry growth
- All businesses/geographies on target except Turkey
 - Turkey sales flat on account of twin impact of currency depreciation and regulatory changes





Business Highlights for the quarter (Q1'19)



Investments in Vizag API bearing fruits

Revenue Growth(%)

15.5

Growth to top 5 players

4x

US filings in quarter

02

CEP Approvals in quarter

02

Largest filings amongst Generic Companies in US

	US	CEPs	Other Reg	Total validated
Q1FY19	2	-	1	3
Cumulative	12	10	23	24

API business Key Highlights

- API Business gains further traction with a growth of 15.5%
- Strategy of being partner of choice for Global 'Top 5' paying off
 - Global 'Top 5' companies now account for 30% of API biz, as against 10% in FY15
 - Four-fold increase in sales to Global 'Top 5' in the period
- EIR received from USFDA for Vizag site for the recent inspection in March 2018
- Initiated validation supplies of 2 new NSAID's for US companion market, both with no generics in the market
- 2 filings in US and 2 CEP approvals during the quarter



R&D to drive value creation in FDF business

Revenue Growth(%)

New products launched

23.1 10+

Under Development

Market Coverage

30+ 95+

Global R&D program Highlights

- 3 new product validations completed – including 1st injectable
- Portfolio of injectable developments finalised, 8 in phase-1 to leverage Bremer site

FDF business Key Highlights

- Robust growth across geographies, led by Europe (14%+), Latam (17%+) and Emerging Markets (31%+)
- Turkey sales up by 16%+ on constant currency, new measure to control abuse of anti-microbials impact sales

Update on new markets

- Alivira France – Largest Animal health market in Europe
 - Launch with 4 companion animal product
 - Commercial operation to commence in Q3'19
- Alivira Ukraine – 9th largest poultry market in the world
 - First registrations achieved - 5 products registered
 - Commercial operations to start Q2'19

Global Formulation R&D program gains momentum

- 30+ products in development in India and Spain for the regulated markets of US, EU and ANZ
- Includes 5 products for US with first filing in Q1'20
- Commercialisation leveraging the robust front-end platform across key markets





Establish Bremer as an injectable site for Regulated Markets (EU & USA)

- Emphasis on high value injectable products backed by the R&D, leveraging the Group's experience in the space
- 8 injectable products shortlisted for development in phase 1
- 1st validation batch planned in Q3'19



Site Enhancements Initiated

- Enhance site injectable manufacturing capacities for mid-term goals
- Extending range of pack type & size range to meet market requirements



Near term visibility

- Business in emerging market to drive breakeven by Q4'19



Turkey- Changes in business environment favour us

- World over, regulations being introduced for judicious use of anti-microbials in production animals including veterinarian supervision
- Turkey has taken the lead in terms of global practices given their large focus on production animals, with two new initiatives – E-Prescription (ER) and Veterinary Pharmaceutical Product Tracking (ITS)
- Resultant slow-down in primary sales in Q1 as market adjust to the new system, normalization expected in H2

Changes by Authority

- Introduction of E-Prescription (“ER”) for the veterinary clinics and Veterinary Pharmaceutical Product Tracking (“ITS”) for the manufacturers and the distributors, applicable from March 2018
- Purpose of the system is to control residues in the food producing animals

Impact on Veterinarian

- ER stipulates veterinarian should introduce all pharmaceutical products for tag of animals through front end connecting to ministry website
- ITS covers the entire manufacturing and sales cycle starting from API sourcing, manufacturing to product sales

Impact on Business

- Veterinarians and the distributors took time to introduce inventory to ITS while the manufacturers were on board mandatorily as the manufacturing was tracked from the import of the API
- The market experiencing a period of low primary sales






**Continued focus on execution and
strong fundamentals**




Strong Execution Continues

All values in ₹ mn

Revenue growth



EBITDA growth



Consolidated Income Statement

All values in ₹ mn

FY18 Audited	PARTICULARS	Q1'19 Unaudited	Q4'18 Audited	Q1'18 Unaudited
8,494	Revenue from Operations	2,352	2,328	1,942
(4,625)	Material Consumption	(1,265)	(1,235)	(1,061)
3,870	Gross Margin	1,086	1,093	881
45.6%	%	46.2%	46.9%	45.4%
(2,999)	Operating Expenses	(837)	(785)	(735)
871	EBITDA	250	308	147
10.3%	%	10.6%	13.2%	7.6%
(41)	Exchange Gain / (Loss)	(25)	(6)	4
166	Other Income	18	29	36
(331)	Finance Cost	(78)	(97)	(61)
(413)	Depreciation	(96)	(95)	(101)
(15)	Exceptional Items	-	(15)	-
236	Earnings Before Tax	69	125	25
(135)	Taxes	(24)	(41)	(19)
102	Earnings After Tax	45	84	6
93	Minority Interest	12	52	0
9	Earnings post minority	33	33	6
4,206	Earnings from discontinued ops	-	3,963	17
4,216	Earnings for the year	33	3,995	22




Key Balance Sheet items


All values in ₹ mn

Particulars	30-Jun-18	31-Mar-18	Remarks
Shareholders' funds	5,815	6,476	Fair valuation of Strides shares
Minority Interest	384	370	
Borrowings	3,092	3,046	Currency impact on \$/€ loans
Cash	527	598	Bremer acquisition
Investments	1,446	2,217	Fair valuation of Strides shares
Tangible Assets	2,292	2,269	
Intangible Assets	2,757	2,671	
Working Capital	2,559	2,483	Bremer acquisition


Net debt to EBITDA




Net Debt to Equity



Current ratio







Thank You

SeQuent Scientific Limited
CIN: L99999MH1985PLC036685

Registered Office:
301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,
Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra
Tel No: +91 22 4111 4777 | Fax No: +91 22 4111 4754
Website: www.sequent.in | E-mail id: info@sequent.in

SeQuent Scientific Announces Q1FY19 Financial Results

Reports 70% growth in EBITDA with 21% year on year growth in revenues

Mumbai, August 9, 2018: SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the quarter ended June 30, 2018 (Q1FY19)

Financial Highlights

Particulars	Q1FY19	Q1FY18	Growth (%)
Revenues	2,352	1,942	21%
EBITDA	250	147	70%
EBITDA %	10.6%	7.6%	300 bps
PAT	45	6	650+%

All values in ₹mn

Commenting on the Q1FY19 results, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: "We delivered robust growth in revenue with our improved operating leverage leading to a 300 basis point improvement in the margins. The performance would have been even better had we not witnessed the currency headwinds in Turkey (-17%) and Brazil (-10%) coupled with regulatory changes in Turkey which impacted our primary sales."

He further added "Our recent Bremer acquisition in Germany has helped us shape a valuable injectables strategy for regulated markets. With 12 API filings in US, we have the largest filings for any generic companies in US. We stay confident of delivering the strategic and financial outcomes for FY19 as our API business gains momentum and Europe gains further traction driven by ~25 new launches planned across geographies."

Detailed presentation on the performance forms part of this press release.

Earnings Call with Investors

The Company will conduct an Earnings call at **9 AM IST on August 10th, 2018** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

The other numbers are listed in the conference call invite which is posted on the website of the Company.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has seven manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

The human API business of Sequent was recently demerged into Solara Active Pharma Sciences Ltd. (Solara), with an appointed date of 1st October 2017.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

sbubna@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra,
India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.